Media ReleasesNoxopharm

View All Noxopharm News


Noxopharm, 2018 Annual General Meeting Presentation

Noxopharm at-a-glance

• Australian biotechnology company. Offices Sydney, New York, Hong Kong

• Playing to our strength.... isoflavonoid drug platform

• Aiming to bring Veyonda® to market as a first-in-class companion drug to radiotherapy

• Mixture of out-licensing and in-house sales/marketing

• Cash: AUD$9.6 million (Sept 30) (+ R&D rebate pending)


To view Presentation please download PDF attached:
Download this document